BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiu G, Jin Z, Chen X, Huang J. Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China. Glob Health Med. 2020;2:306-311. [PMID: 33330825 DOI: 10.35772/ghm.2020.01051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Bai H, Meng S, Xiong C, Liu Z, Shi W, Ren Q, Xia W, Zhao X, Jian J, Song Y, Ni C, Gao X, Li Z. Preoperative CECT-based Radiomic Signature for Predicting the Response of Transarterial Chemoembolization (TACE) Therapy in Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2022. [PMID: 35896687 DOI: 10.1007/s00270-022-03221-z] [Reference Citation Analysis]
2 Yang T, Chen Y, Xu J, Li J, Liu H, Liu N. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis. BMC Complement Med Ther 2022;22:21. [PMID: 35078445 DOI: 10.1186/s12906-021-03487-9] [Reference Citation Analysis]
3 Xu Y, Wei FX. A retrospective study of enteral nutrition on immune and inflammatory factors after liver cancer surgery. Medicine (Baltimore) 2021;100:e27718. [PMID: 34871264 DOI: 10.1097/MD.0000000000027718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Chen Z, Wang T, Chen C, Hong X, Yu J, Ma Y, Guo Y, Huang C, He X, Ju W, Chen M. Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:7776389. [PMID: 34712326 DOI: 10.1155/2021/7776389] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kokudo N, Tang W, Kokudo T. Classification of hepatic venous tumor thrombus in hepatocellular carcinoma: should it describe tumor status or predict patient survival? Hepatobiliary Surg Nutr 2021;10:538-40. [PMID: 34430538 DOI: 10.21037/hbsn-21-237] [Reference Citation Analysis]
6 Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(8): 845-855 [PMID: 34457190 DOI: 10.4251/wjgo.v13.i8.845] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wang P, Xue N, Zhang C, Shan S, Jiang Z, Wu W, Liu X. Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells. Oncol Lett 2021;21:274. [PMID: 33732350 DOI: 10.3892/ol.2021.12535] [Cited by in F6Publishing: 2] [Reference Citation Analysis]